This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Nuclear receptor subfamily 2, group F, member 2 (NR2F2; COUP-TFII)	<p>Studies in mice suggest that inhibiting COUP-TFII could help treat cancer. In adult mice, conditional knockout of COUP-TFII reduced angiogenesis and suppressed growth of human melanoma xenografts compared with what occurred in wild-type animals. In a mouse model of mammary tumorigenesis, mice lacking COUP-TFII developed fewer spontaneous tumors than mice expressing the protein. Next steps include screening for a COUP-TFII antagonist.</p> <p>SciBX 3(4); doi:10.1038/scibx.2010.112 Published online Jan. 28, 2010</p>	Findings unpatented; available for licensing in animals for screening ligands and verifying use of antagonists as cancer treatment	<p>Qin, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 11, 2010; doi:10.1073/pnas.0914619107</p> <p>Contact: Sophia Y. Tsai, Baylor College of Medicine, Houston, Texas e-mail: stsai@bcm.tmc.edu</p> <p>Contact: Ming-Jer Tsai, same affiliation as above e-mail: mtsai@bcm.tmc.edu</p>